126 related articles for article (PubMed ID: 23433587)
21. Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
Tilghman SL; Sabnis G; Brodie AM
Horm Mol Biol Clin Investig; 2010 Dec; 3(1):357-66. PubMed ID: 25961207
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1.
Anzick SL; Azorsa DO; Simons SS; Meltzer PS
BMC Cancer; 2003 Sep; 3():22. PubMed ID: 12964942
[TBL] [Abstract][Full Text] [Related]
23. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
24. [Melatonin suppressing the proliferation of E2-induced pituitary prolactin-secreting tumor in rat involves the effects of estrogen receptor].
Yang QH; Xu JN; Zhang R; Gao L; Xu RK
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2006 May; 22(2):174-8. PubMed ID: 21162234
[TBL] [Abstract][Full Text] [Related]
25. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.
Fleming FJ; Myers E; Kelly G; Crotty TB; McDermott EW; O'Higgins NJ; Hill AD; Young LS
J Clin Pathol; 2004 Oct; 57(10):1069-74. PubMed ID: 15452162
[TBL] [Abstract][Full Text] [Related]
26. [Expression of galectin-3 in invasive prolactinomas].
Wang H; Wang MD; Ma WB; Yang D; Shi YF; Kong YG; Li SF; Li ZH; Wang RZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):380-1. PubMed ID: 16038281
[TBL] [Abstract][Full Text] [Related]
27. Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation.
Torres-Arzayus MI; Zhao J; Bronson R; Brown M
Cancer Res; 2010 May; 70(10):4102-11. PubMed ID: 20442283
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
29. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
[TBL] [Abstract][Full Text] [Related]
30. Chaperonin CCT-mediated AIB1 folding promotes the growth of ERα-positive breast cancer cells on hard substrates.
Chen L; Zhang Z; Qiu J; Zhang L; Luo X; Jang J
PLoS One; 2014; 9(5):e96085. PubMed ID: 24788909
[TBL] [Abstract][Full Text] [Related]
31. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis.
Kuang SQ; Liao L; Wang S; Medina D; O'Malley BW; Xu J
Cancer Res; 2005 Sep; 65(17):7993-8002. PubMed ID: 16140972
[TBL] [Abstract][Full Text] [Related]
32. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
33. Prolactinomas in male and female patients: a comparative clinicopathologic study.
Calle-Rodrigue RD; Giannini C; Scheithauer BW; Lloyd RV; Wollan PC; Kovacs KT; Stefaneanu L; Ebright AB; Abboud CF; Davis DH
Mayo Clin Proc; 1998 Nov; 73(11):1046-52. PubMed ID: 9818037
[TBL] [Abstract][Full Text] [Related]
34. Expression of nuclear receptors and cofactors in human endometrium and myometrium.
Vienonen A; Miettinen S; Bläuer M; Martikainen PM; Tomás E; Heinonen PK; Ylikomi T
J Soc Gynecol Investig; 2004 Feb; 11(2):104-12. PubMed ID: 14980312
[TBL] [Abstract][Full Text] [Related]
35. Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas.
Mukdsi JH; De Paul AL; Petiti JP; Gutiérrez S; Aoki A; Torres AI
Acta Neuropathol; 2006 Oct; 112(4):491-501. PubMed ID: 16823503
[TBL] [Abstract][Full Text] [Related]
36. Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen.
Mukdsi JH; De Paul AL; Muñoz S; Aoki A; Torres AI
Histochem Cell Biol; 2004 Jun; 121(6):453-62. PubMed ID: 15221415
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptors in human pituitary tumors.
Burdman JA; Pauni M; Heredia Sereno GM; Bordón AE
Horm Metab Res; 2008 Aug; 40(8):524-7. PubMed ID: 18398784
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness.
Xu Y; Chen Q; Li W; Su X; Chen T; Liu Y; Zhao Y; Yu C
Oncogene; 2010 Jun; 29(23):3386-97. PubMed ID: 20305690
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the status of the novel estrogen receptor α (ERα) coactivator p72 in endometrial cancer and its cross talk with erbB-2 in the transactivation of ERα.
Zhao L; Watanabe M; Yano T; Yanagisawa J; Nakagawa S; Oishi H; Wada-Hiraike O; Oda K; Minaguchi T; Yasugi T; Kato S; Taketani Y
Mol Med Rep; 2008; 1(3):387-90. PubMed ID: 21479421
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-beta regulation of estradiol-induced prolactinomas.
Hentges S; Sarkar DK
Front Neuroendocrinol; 2001 Oct; 22(4):340-63. PubMed ID: 11587556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
